Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. Issue 6 (April 2015)

• Record Type: Journal Article
• Authors: Le Cesne, Axel; Ray-Coquard, Isabelle; Duffaud, Florence; Chevreau, Christine; Penel, Nicolas; Bui Nguyen, Binh; Piperno-Neumann, Sophie; Delcambre, Corinne; Rios, Maria; Chaigneau, Loic; Le Maignan, Christine; Guillemet, Cecile; Bertucci, François; Bompas, Emmanuelle; Linassier, Claude; Olivier, Thimotée; Kurtz, Jean-Emmanuel; Even, Caroline; Cousin, Philippe; Yves Blay, Jean; French Sarcoma Group
• Is Part Of: European journal of cancer. Volume 51:Issue 6(2015:Apr.)
• Page Start: 742
• Page End: 750
• Publication Date: 2015-04
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.01.006
• Languages: English
• ISSNs: 0959-8049

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab010"> <title id="st110">Abstract</title> <sec> <title id="st015">Aim</title> <p id="sp0010">The French Sarcoma Group performed this retrospective analysis of the 'RetrospectYon' database with data of patients with recurrent advanced soft tissue sarcoma (STS) treated with trabectedin 1.5 mg/m<sup>2</sup> as a 24-h infusion every three weeks.</p> </sec> <sec> <title id="st020">Methods</title> <p id="sp0015">Patients who achieved non-progressive disease after six initial cycles could receive long-term trabectedin treatment until disease progression.</p> </sec> <sec> <title id="st025">Results</title> <p id="sp0020">Overall, 885 patients from 25 French centres were included. Patients received a median of four trabectedin cycles (range: 1–28). The objective response rate was 17% (six complete/127 partial responses) and 50% (<italic>n</italic> = 403) of patients had stable disease for a disease control rate of 67%. After a median follow-up of 22.0 months, median progression-free survival (PFS) and overall survival (OS) were 4.4 and 12.2 months, respectively. After six cycles, 227/304 patients with non-progressive disease received trabectedin until disease progression and obtained a significantly superior median PFS (11.7 versus 7.6 months, <italic>P </italic>< 0.003) and OS (24.9 versus 16.9 months, <italic>P</italic> < 0.001) compared with those who stopped trabectedin treatment. Deaths and unscheduled hospitalisation attributed to drug-related events occurred in 0.5% and 9.4% of patients, respectively.</p> </sec> <sec> <title id="st030">Conclusion</title> <p id="sp0025">The results of this real-life study demonstrate that treatment with trabectedin of patients with STS yielded comparable or improved efficacy outcomes versus those observed in clinical trials. A long-term treatment with trabectedin given until disease progression is associated with significantly improved PFS and OS.</p> </sec> </abstract>